Lexeo Therapeutics, Inc. (LXEO) EBIAT (2022 - 2023)
Lexeo Therapeutics' EBIAT history spans 2 years, with the latest figure at -$14.2 million for Q4 2023.
- For Q4 2023, EBIAT rose 2.63% year-over-year to -$14.2 million; the TTM value through Dec 2023 reached -$66.4 million, changed N/A, while the annual FY2024 figure was -$98.3 million, 48.04% down from the prior year.
- EBIAT for Q4 2023 was -$14.2 million at Lexeo Therapeutics, up from -$20.1 million in the prior quarter.
- Across five years, EBIAT topped out at -$13.4 million in Q2 2023 and bottomed at -$20.1 million in Q3 2023.